Researchers have discovered an unexpected superpower in GLP-1 medications: the blockbuster weight-loss and diabetes drugs appear to dramatically reduce cravings for alcohol, opioids, cocaine, nicotine, cannabis, and other addictive substances.
The findings, published in The BMJ, come from a landmark analysis of more than 606,000 U.S. veterans conducted at Washington University School of Medicine in St. Louis. The scale of the study and the consistency of the results across multiple drug categories have surprised even the researchers.
Among veterans without prior substance use disorders, those taking GLP-1 medications were substantially less likely to develop addiction problems. GLP-1 users showed a 14% lower risk of developing any substance use disorder compared to those on other diabetes medications. The protection varied by substance: opioid addiction risk dropped 25%, nicotine and cocaine risks fell 20%, cannabis 14%, and alcohol 18%.
The study extrapolated these numbers to mean seven fewer new addiction diagnoses per 1,000 people taking the drugs.
Even more striking were the results for people already struggling with addiction. Veterans with existing substance use disorders who used GLP-1 medications experienced a 40% reduction in overdoses and a 50% reduction in drug-related deaths within three years. Emergency department visits fell 30%, and hospitalizations dropped 25%. The researchers estimate this translates to 12 fewer serious addiction-related events per 1,000 users.
The medications examined in the study included semaglutide, liraglutide, and dulaglutide. The comparison group took SGLT2 inhibitors, another class of diabetes medication.
What makes these findings potentially transformative is that GLP-1 drugs appear to work against addiction itself, not against specific substances. Most addiction treatments target a single drug: nicotine patches work for smoking but not alcohol, methadone addresses opioid dependence but nothing else. The GLP-1 effect spans nearly all major addictive substances uniformly.
Senior researcher Ziyad Al-Aly, a clinical epidemiologist at WashU Medicine, explained the mechanism. "GLP-1 medication really works against all major substances, and it works uniformly, not because it acts against alcohol or opioids or nicotine specifically, but because it is likely acting against the craving itself. It blunts that craving that pulls people toward whatever they're addicted to."
The theory rests on neurobiology. GLP-1 receptors exist in brain regions that process reward, suggesting the drugs could suppress the underlying drives of addiction. Rather than treating each substance separately, the medication may quiet a shared biological pathway that fuels craving across different addictions.
Al-Aly drew a parallel to how patients describe GLP-1 effects on food. "People taking these drugs for obesity often describe a quieting of 'food noise,' the persistent preoccupation with food that drives overeating," he said. "What our study suggests is something broader: GLP-1 drugs may also quiet what I call 'drug noise,' the relentless craving that drives addiction across substances."
The observations began when patients spontaneously reported losing interest in alcohol and cigarettes after starting GLP-1 treatment. Earlier smaller studies had hinted at such effects, but the new research is the largest to examine the phenomenon across multiple substances and most serious outcomes.
The implications stretch beyond addiction treatment alone. For the millions of Americans already taking these drugs for weight loss or diabetes, the findings suggest a potential hidden benefit. For patients with both obesity and addiction, one medication could address both simultaneously.
Researchers say the findings justify conducting randomized clinical trials specifically designed to test GLP-1 drugs as addiction treatments. Such studies would need to measure effects on overdose and death, outcomes that matter most to public health.
The work was funded by the Department of Veterans Affairs and involved analysis of electronic health records over up to three years of follow-up. The researchers reviewed outcomes for participants divided into two groups: those without substance use disorders at baseline and those with diagnosed disorders.
Author Jessica Williams: "If these results hold up in controlled trials, we could be looking at a fundamental shift in how we treat addiction, not by chasing each substance separately, but by silencing the biological engine that drives craving in the first place."
Comments